

Supplementary Materials

Table S1. Epidemiological and clinical feature of the statistically matched patients for the outcome analysis.

	2008-2019 (N = 109)	2020 (N = 109)	<i>p</i>	<i>d</i>
Male sex, N (%)	50 (45.9)	42 (38.5)	0.337	0.170
Age, year, median (IQR)	65 (52–77)	64 (47–80)	0.718	0.040
Comorbidities, N (%)	84 (77.1)	85 (78)	1.000	0.030
Amylase, U/l, median (IQR)	595 (282–1199)	670 (203–1132)	0.857	0.024
Lipase, U/l, median (IQR)	1107 (408–3133)	1309 (316–2782)	0.497	0.090
Etiology, N (%)				
Biliary	55 (50.5)	46 (42.2)	0.015	0.120
Alcohol	6 (5.5)	16 (14.7)		
ERCP	2 (1.8)	8 (7.3)		
Hypertriglyceridemia	2 (1.8)	5 (4.6)		
Drugs	5 (4.6)	2 (1.8)		
IPMN	7 (6.4)	12 (11)		
Post-surgical	3 (2.8)	0		
Idiopathic	29 (26.6)	20 (18.4)		
Familial	0	0		
Severity, N (%)				
Mild	91 (83.5)	93 (85.3)	0.127	0.039
Moderately severe	16 (14.7)	12 (11)		
Severe	2 (1.8)	4 (3.7)		